title: [The role of oral fluoropyrimidines in colorectal cancer treatment--a review].
abstract: Oral fluoropyrimidines, such as uracil plus tegafur (UFT), S-1 and capecitabine, have been developed and evaluated in the treatment of colorectal cancer. Their efficacy and safety are not inferior to infusional FU regimens. They provide more convenient therapy and better QOL. Careful observation and management of adverse events to preserve treatment compliance is important.
authors.affiliation: Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
authors.forename: Yoko
authors.initials: Y
authors.lastname: Toda
authors.forename: Nozomu
authors.initials: N
authors.lastname: Machida
authors.forename: Narikazu
authors.initials: N
authors.lastname: Boku
mesh_terms: D000284:Administration, Oral; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D015179:Colorectal Neoplasms / Q000188:drug therapy*; D006801:Humans; D011743:Pyrimidines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011788:Quality of Life
chemical_list: D000970:Antineoplastic Agents; D011743:Pyrimidines; C029269:5-fluoropyrimidine